Neumora

Neumora

Develops precision medicines for CNS disorders

Overview

Preparing a concise company summary for Neumora Therapeutics based on provided description.

About Neumora

Simplify's Rating
Why Neumora is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Neumora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NMRA-511 targets Alzheimer’s agitation, a high-unmet-need dementia segment.[2][5]
  • NMRA-898 could address schizophrenia with differentiated M4 receptor biology.[5][10]
  • NMRA-215 adds a cardiometabolic expansion path beyond CNS-only programs.[2][5]

What critics are saying

  • Navacaprant failed Phase 3 endpoints and was discontinued, destroying the lead asset.[2]
  • Workforce cut of 35% reduces execution capacity across remaining programs.[2]
  • Clinical-stage pipeline remains unproven, leaving Neumora dependent on future binary readouts.[2][5]

What makes Neumora unique

  • Precision medicine platform targets brain diseases with novel mechanisms.[4][8]
  • Pipeline spans neuropsychiatric, neurodegenerative, and metabolic indications.[5][10]
  • Programs use translational and computational tools for patient subtyping.[3][4]

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$916.5M

Above

Industry Average

Funded Over

4 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Parental Leave

Performance Bonus

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
BioGeneration Ventures
Jul 10th, 2025
Brenig Therapeutics Announces Appointments of David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer, Expands Pipeline

Dr. Dam joins Brenig from Neumora Therapeutics, where she was Vice President of Clinical Development, leading strategy and execution across neuropsychiatry and neurodegeneration programs.

Recently Posted Jobs

Sign up to get curated job recommendations

Neumora is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →